Küleon, LLC
Press Release | April 13, 2023:
Within Küleon’s third patent publication the company discloses a wide array of conformationally-constrained ligands that exhibit unique selectivity for serotonin receptor subtypes.
Press Release | February 23, 2023:
Within this patent publication Küleon discloses novel analogs having alkoxy, alkylthio and alkylseleno residues, rendering many of these compounds completely inactive at the 5-HT2B receptor.
Press Release | February 16, 2023:
Kuleon’s first patent application, disclosing its proprietary molecular scaffolds and thousands of novel compounds, published by World Intellectual Property Office.
